文献速递临床免疫质量管理与危急值

分化型甲状腺癌随访中更换甲状腺球蛋白及抗体检测方法的临床影响

Clinical implications of changing thyroglobulin and antithyroglobulin antibodies analytical methods in the follow-up of patients with differentiated thyroid carcinoma.
PubMed 文献 · Clin Chim Acta · 2023-07-27

该研究在82份血清样本(60份来自分化型甲状腺癌患者)中比较了Elecsys与Access免疫分析法检测甲状腺球蛋白(Tg)和抗甲状腺球蛋白抗体(Ab-Tg)的差异。Elecsys测得的Tg值更高,平均偏差5.03 ng/mL(95%CI:-14.14-24.21),但DTC患者治疗反应分类几乎完全一致(kappa=0.833)。Ab-Tg相关性差(r=0.5394),将Elecsys cut-off降至43 IU/mL后阳性/阴性分类一致性从kappa=0.607提升至0.650。结论认为更换检测方法对患者管理的临床影响最小,但仍需谨慎个性化随访。

要点

  • Elecsys测得的Tg值高于Access,平均偏差5.03 ng/mL(95%CI:-14.14-24.21)。
  • DTC患者治疗反应分类一致性几乎完美(kappa=0.833)。
  • Ab-Tg相关性差(r=0.5394),cut-off调整可改善分类一致性。

核心结论

  • 更换Tg和Ab-Tg检测方法虽存在分析偏差,但对DTC患者管理的临床影响最小。
  • 更换方法后仍需谨慎个性化随访,尤其是Tg水平在0.2-1 ng/mL的患者。

研究设计与样本

  • 研究在82份血清样本(60份来自DTC患者)中,用Elecsys和Access免疫分析法定量Tg和Ab-Tg。
  • 前瞻性研究采用个性化随访,评估Tg结果需分析确认的比例及确认率。

主要发现

  • Elecsys免疫分析法测得的Tg值高于Access,平均偏差5.03 ng/mL(95%CI:-14.14-24.21)。
  • DTC患者中,治疗反应分类的kappa指数为0.833,几乎完全一致。
  • 反应未确定患者中出现差异,Access更倾向于细分分类。
  • Ab-Tg相关性差,r=0.5394。
  • Elecsys cut-off降至43 IU/mL时,阳性/阴性分类一致性kappa从0.607提高至0.650。

关键数值与推荐

  • Elecsys与Access测Tg平均偏差5.03 ng/mL(95%CI:-14.14-24.21)。
  • DTC患者治疗反应分类kappa指数=0.833。
  • Ab-Tg相关性r=0.5394。
  • Elecsys cut-off为43 IU/mL时,阳性/阴性分类kappa=0.650(原为0.607)。
  • 前瞻性随访中6.3%的Tg结果需分析确认,93%被确认。

临床怎么用

  • 更换Tg或Ab-Tg检测方法后,应认识到分析偏差但临床影响可能有限。
  • 对Tg水平在0.2-1 ng/mL的患者,更换方法后需谨慎个性化随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients' response to treatment in differentiated thyroid cancer (DTC) is classified according to serum thyroglobulin concentrations (Tg), usually using the American Thyroid Association guidelines and considering potential interfering anti-thyroglobulin antibodies (Ab-Tg). We aim to evaluate the clinical implications of changing Tg and Ab-Tg quantification method. MATERIAL AND METHODS: Tg and Ab-Tg were quantified in 82 serum samples (60 from DTC patients) by Elecsys and Access immunoassays. RESULTS: Elecsys immunoassay rendered higher values of Tg than Access: mean bias 5.03 ng/mL (95%CI:-14.14-24.21). In DTC patients, there was an almost perfect agreement for response classification (kappa index = 0.833). Discrepancies appeared in patients with undetermined response, with a more tendency to subclassification with Access. Ab-Tg showed a poor correlation (r = 0.5394). When Elecsys cut-off was reduced to 43 IU/mL, agreement for positive/negative classification improved from a kappa index of 0.607 to 0.650. Prospective study with personalized follow-up showed that only 6.3% of Tg results required an analytical confirmation, being confirmed 93% of them. CONCLUSIONS: Despite the biases observed, clinical impact of an analytical change is minimal in patients' management. However, cautious and personalized follow-up period after the change is still mandatory, especially in patients with Tg levels between 0.2 and 1 ng/mL.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Deza S, Maroto J, Tellechea O, et al. Clinical implications of changing thyroglobulin and antithyroglobulin antibodies analytical methods in the follow-up of patients with differentiated thyroid carcinoma. Clin Chim Acta. 2023. PMID: 37516333. doi:10.1016/j.cca.2023.117502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。